Drug profile · INN
insulin detemir recombinant
LEVEMIR FLEXTOUCH
insulin detemir recombinant (LEVEMIR FLEXTOUCH) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — insulin detemir recombinant
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
insulin detemir recombinant (LEVEMIR FLEXTOUCH) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is insulin detemir recombinant?
insulin detemir recombinant (LEVEMIR FLEXTOUCH) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for insulin detemir recombinant?
LEVEMIR FLEXTOUCH is a marketed brand name for insulin detemir recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin detemir recombinant?
insulin detemir recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.